BioSpace News Archive

“With 1,000 Hybrid ORs installed worldwide, we have more experience in designing and implementing these spaces than any other company,” said Chris Odom, President of Surgical Workflows, Getinge USA.

In Japan, the full Volpara Enterprise suite of products has received regulatory approval as a Class II medical device.

All prescriptions of Sucraid (sacrosidase) Oral Solution will be filled and distributed exclusively by U.S. Bioservices.

The app update includes support for DarioHealth’s new Lightning compatible device for iPhone 7 and iPhone 8 which was recently awarded the CE Mark.

Daiichi Sankyo today announced the first patient has been enrolled in DESTINY-Gastric01, a pivotal phase II study in Japan and South Korea evaluating the safety and efficacy of DS-8201, an investigational HER2-targeting ADC, in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma resistant or refractory to trastuzumab.

AUVI-Q is a compact epinephrine auto-injector with industry-first features, including a voice prompt system that guides a user with step-by-step instructions through the delivery process, and a needle that automatically retracts following administration.

SXC-2023 has demonstrated a compelling profile across a range of non-clinical studies.

The collaborative study was led by Theodore Jardetzky, PhD, Professor of Structural Biology at Stanford University and involved researchers at Stanford University and Northwestern University.

The two new execs bring global operations and commercialization expertise to the company.

The event will bring together leading expert allergists to discuss the emerging treatment landscape in peanut allergy.